

CIDR Health Retirement Study

Imputation Report - 1000 Genomes Project reference panel

August 14, 2012

Contents

- I. [Summary and recommendations for dbGaP users](#)
- II. [Study data](#)
 - a. Samples
 - b. SNPs
 - c. Data formatting
 - d. Pre-phasing
- III. [Reference panel](#)
- IV. [Strand alignment](#)
- V. [Imputation software and computing resources](#)
- VI. [Imputation output](#)
 - a. Phased output
 - b. Genotype probabilities
 - c. Quality metrics
 - d. Masked SNP analysis
 - e. Downstream analysis
- VII. [Summary](#)
- VIII. [References](#)
- IX. [Web resources](#)
- X. [Tables](#)
- XI. [Figures](#)
- XII. [Supplementary files](#)

I. Summary and recommendations for dbGaP users

Genotype imputation is the process of inferring unobserved genotypes in a study sample based on the haplotypes observed in a more densely genotyped reference sample^{1,2}. The University of Washington Genetics Coordinating Center (GCC) used IMPUTE2 software³ to perform genotype imputation in the Health Retirement Study (HRS). Imputed results are provided as the probability of each of the three genotype states at each SNP, for every study participant. We recommend incorporating these imputed probabilities into any downstream analyses, rather than taking the most likely imputed genotype. Quality metrics are provided that can be used for filtering imputation results on a per-SNP basis. For a detailed description of genotype quality control (QC) on this project, please see the report available through dbGaP (database of Genotypes and Phenotypes; phs000428.v1.p1 and phg000207.v1).

II. Study data

a. Samples

The Health Retirement Study (HRS) is a large, longitudinal study of Americans over age 50 aimed at monitoring health, social, economic, and numerous other factors related to aging and retirement. A random subset of the ~26,000 total participants was selected to participate in enhanced face to face interviews and biological specimen collection (blood and/or saliva), in 2006 and 2008. Of these collected samples, 13,129 were put into genotyping production at the Center for Inherited Disease Research (CIDR), in 2011. After the GCC's standardized QC procedures⁴, genotypes were available for 12,507 unique participants.

Prior to imputation, HRS samples were filtered following modified versions of the GCC recommendations described in the genotype QC report. Fifty-three study samples were excluded due to missing call rate (MCR) greater than 2%. Thus, imputed data are provided for 12,454 samples.

Figure 1 shows a principal component analysis (PCA) of all study participants, in which the self-identified race and ethnicity of HRS samples correlate well with HapMap reference populations. In the interest of (1) imputing the maximum number of study samples and (2) avoiding artifactual differences between separate imputation groups, no PCA-based sub-setting or filtering of study samples was done prior to imputation. Rather, all study participants were imputed together in one group. While all participants were expected to be unrelated, a number of familial relationships were detected during the genotype QC process: 45 full sibling pairs, 20 half-sib-like pairs (half-sib/avuncular/grandparent-grandchild), and 25 parent-offspring pairs. The relatedness between the parent-offspring pairs was taken into account during the pre-phasing step, as discussed further in section II-d. Relatedness between full siblings and half-sib-like-pairs, however, could not be incorporated into the pre-phasing algorithm and thus were ignored.

The subject level identifier ("subjectID" in annotation files) was used as the individual identifier throughout, which can be mapped to both the local subjectID ("local.subjectID")

and the sample scan identifier (“scanID” corresponding to one genotype scan) using the sample-subject mapping files provided in the Supplementary Files (section XII).

b. SNPs

The HRS genome-wide association study (GWAS) was genotyped on the Illumina HumanOmni2.5-4v1 SNP array, designed to human genome build 37. For the purposes of imputation, study SNPs were selected using CC recommended SNP quality filters described in the genotyping QC report. A summary of initial input SNPs is shown in Table 1; a list of these SNPs is available in the Supplementary Files. Observed genotypes (which have a probability of 1) are included in the imputation output. Where an observed study SNP had sporadic missing data, the missing genotypes were imputed in the same manner as the completely unobserved SNPs and should be treated with the same caveats. Additionally, SNPs genotyped in the study but failing pre-imputation quality filters may also appear in imputed results, when available in the reference panel.

This data formatting pipeline could result in discrepancies between observed genotypes posted in the primary dbGaP GWAS release and these imputed data. The SNP annotation files accompanying this report can be used to differentiate between observed study SNPs used in the imputation input and the imputed SNPs. We refer to the former set of SNPs as the “imputation basis” and to the latter as “imputation target” SNPs. These terms are analogous to the IMPUTE2 definitions of “type 2” and “type 0” SNPs, respectively. (Note that “type 1” SNPs occur only when more than one reference panel is used with IMPUTE2.) Lastly, we refer to study SNPs that do not occur in the reference as “study only” SNPs, or “type 3” in IMPUTE2. See Figure 2 for a visual representation of these SNP types.

c. Data formatting

The study genotype data were initially accessed from the binary PLINK⁵ file available in the dbGaP release, “CIDR_HRS_Top_subject_level_filtered.” The Illumina annotation file, which included genomic strand information, was thus used to identify the SNPs requiring a strand flip to convert the Illumina TOP allele to the “+” strand of the human genome reference assembly (see section IV). When extracting data from the binary PLINK file, we (1) subset out by chromosome; (2) set haploid genotypes (male chromosome X) called as heterozygotes to missing; (3) extracted only study SNPs passing the quality filter; (4) specified a keep list of study samples (i.e. where overall MCR \leq 2%); (5) updated parental IDs to reflect known familial relationships; and (6) specified a list of SNPs that required a strand flip to align with the “+” strand, based on Illumina annotation. Below is an example of the command line syntax used to create the filtered .ped files, for generic chromosome “#”:

```
plink --bfile CIDR_HRS_Top_subject_level_filtered \  
--extract snp.qualfilter.txt --flip fliplist.txt \  
--keep sampkeep_chr#.txt --update-parents update_parents.txt \  
--set-hh-missing --chr # --make-bed --out HRS_chr#
```

d. Pre-phasing

While phasing and imputation are generally done in tandem, an alternative approach is to phase the diploid study data prior to imputation. This “pre-phasing” approach is favored by many because (1) imputing into phased haplotypes is much faster than imputing into unphased genotypes and (2) pre-phased data facilitates future updates to imputation, as improved reference panels become available⁶. An added benefit to pre-phasing is that it can utilize known relatedness, which is not currently computationally tractable when phasing and imputation are done jointly. Although pre-phasing may introduce a small loss of accuracy vis-à-vis omitting haplotype uncertainty information in the imputation step, the advantages appear to outweigh the disadvantages – especially for large datasets such as HRS.

The “best practices” guidelines in the IMPUTE2 documentation (see Web resources) recommend pre-phasing with the SHAPEIT⁶ software package, currently released as v1.r532. While in the planning stages of HRS imputation, the GCC was informed by the SHAPEIT authors they had developed a new version of SHAPEIT that was “more accurate than version 1, especially in large datasets [like HRS]” (personal communication, Jonathan Marchini, May 9, 2012). The authors kindly shared with the GCC a pre-release version of SHAPEIT2 and details of their manuscript, which is currently under review. We tested the pre-release version of SHAPEIT2 in our HRS samples (chromosome 22 only) and determined it would greatly accelerate the HRS imputation project without incurring any loss in accuracy. (Specifically, imputing into unphased genotypes on chromosome 22 required ~63 compute days, compared with a total of 5 compute days to pre-phase with SHAPEIT2 and impute into the pre-phased haplotypes.)

In addition to the computational benefit afforded by SHAPEIT2, it can also utilize relatedness between samples (trios and duos) when phasing autosomes. The initial PLINK dataset did not reflect the family structure identified during genotype cleaning. Thus, prior to phasing, we updated the parental IDs for offspring in parent-offspring pairs, by using the “`--update-parents`” flag when writing out chromosome-specific PLINK files (see previous section). Parent IDs were taken from the kinship coefficient table included in the genotype posting (“`Kinship_coefficient_table.csv`”). Relatedness between the full siblings and half-sib-like relationships, however, could not be used in pre-phasing; thus these samples were left as unrelated. Family structure information is included in the Supplementary Files section of this report. For each participant, we annotate whether they were phased as part of a duo, trio, or as unrelated.

Haplotype phase was determined across all autosomes for 1 trio, 22 duos, and 12,407 unrelated HRS samples. SHAPEIT2 ignores all sample relatedness when phasing chromosome X, thus all 12,454 samples were phased as unrelated on this sex chromosome. Another unique aspect of X chromosome phasing was the need to exclude 8 samples with 100% missing data – i.e. where genotypes across the entire length of the chromosome had

been zeroed out in the filtered PLINK file, due to gross chromosomal anomalies. SHAPEIT2 does not allow any individual with 100% missing data; X was the only chromosome where some HRS samples had anomalies extending across the length of the chromosome.

SHAPEIT2 runtimes varied by chromosome, ranging from 2 to 13 days with an average of 7 days. Below is an example of the command line syntax used to run the SHAPEIT2 program on a generic autosome “#”:

```
shapeit2 --input-bed HRS_chr#.bed HRS_chr#.bim HRS_chr#.fam \  
--input-map genetic_map_chr#_combined_b37.txt -states 200 \  
--output-max HRS_chr#.haps.gz HRS_chr#.gz \  
--thread 8 --output-log shapeit_chr#.log
```

The SHAPEIT2 output files of best-guess haplotypes were subsequently used as input for the IMPUTE2 imputation analyses.

III. Reference panel

Larger reference panels have been shown to increase imputation accuracy^{2,7,8}. To date, haplotypes from Phases 2⁹ and 3¹⁰ of the International HapMap Consortium have served as the reference panel for many imputation analyses. Recent advancements in genome-wide resequencing technology are now beginning to yield alternatives to these historically standard HapMap panels, enabling the imputation of many more and rarer variants^{2,11}. The 1000 Genomes Project aims to “discover, genotype, and provide accurate haplotype information on all forms of human DNA polymorphism in multiple human populations¹².” The completion of the pilot phase resulted in refinement of the Project’s methods for variant calling from the low-coverage sequence data, and these improvements have since been implemented in the production phase (“phase I”). Issued in December 2010, the first phase I release contained data for 629 samples, from the 2010.08.04 sequence alignment. Subsequent releases are expected to increase in both the sample and SNP dimensions. Thus, while the sample size of the pilot project was limited in comparison to HapMap, the larger sample sizes in the ongoing main project will likely further improve rare variant imputation moving forward¹³.

In October 2011, the Project released the first version of the phase I integrated variant set, containing SNPs, insertion/deletions (indels), and structural variants (SVs) in 1,092 samples. This release includes additional samples in most of the 12 populations from the initial phase I release, with the addition of Colombian in Medellin, Colombia (CLM) and Iberian populations in Spain (IBS). The Project has categorized each of these populations into four continental groupings: African (AFR), American (AMR), Asian (ASN), and European (EUR). To impute HRS, we used a worldwide reference panel of all 1,092 samples from the phase I integrated variant set (v3, released March 2012). We downloaded these reference panel data from the IMPUTE2 website (see Web Resources), which had been created from the variant call format (VCF) files available from the Project.

The IMPUTE2 method enables the computationally efficient use of all available reference panel samples, bypassing the problematic step of *a priori* choosing the mixture of haplotypes most representative of the study samples. Instead, when given a worldwide reference, IMPUTE2 will select an appropriate subset of the available reference haplotypes for each study haplotype in each genomic region⁸. While this approach eases the computational burden of using all reference samples, it still may not warrant the imputation of all available reference SNPs (i.e. approximately 40 million variants). Very low minor allele frequency (MAF) SNPs are both harder to impute and, even if imputed error-free, it is unlikely most studies will be sufficiently powered to detect an association at these SNPs in downstream analyses. Therefore, we restricted imputation to SNPs with at least four copies of the minor allele in any one of the four continental groups: AFR, AMR, ASN, or EUR. We assessed each continental panel when choosing imputation target SNPs because of the multiple well-represented self-identified ethnic and racial groups comprising the HRS sample set. In a joint discussion between the GCC and the study investigators, four copies of the minor allele was chosen as a minimum threshold, ultimately yielding ~21 million variants.

We also excluded indels and SVs (approximately 1.5M variants), due to the current lack of information regarding how accurately such variants can be imputed.

IV. Strand alignment

Accurate imputation is dependent upon the study and reference panel allele calls being on the same physical strand of DNA relative to the human genome reference sequence (“reference”). In practice, however, this crucial step is not always straightforward¹⁴. The initial study dataset contained TOP alleles, an Illumina naming method unrelated to “+” or “-” strand orientation¹⁵ (also see Web Resources, Illumina 2006). Because all 1000 Genomes reference panel data are expected to be “+” strand relative to the reference, we initially used Illumina annotation to identify and flip all the SNPs where the TOP allele was not on the “+” strand.

As further assurance of strand consistency, IMPUTE2 automatically addresses strand alignment at strand unambiguous SNPs (i.e. not A/T or C/G variants) by comparing allele labels. That is, where a strand unambiguous SNP in the study data is found to have different nucleotides compared to the reference panel, the strand is flipped in the study data. We did not, however, invoke the additional, optional strand alignment check “-align_by_maf.” This option compares MAF between the reference and study samples at strand ambiguous SNPs (A/T or C/G) and, where necessary, flips the study data to make the minor alleles consistent. This method may be prone to erroneous strand flips at strand ambiguous SNPs with MAF close to 50%. Another disincentive for using the “align_by_maf” option is that allele frequencies are likely to differ between study and reference samples due to different ethnic composition. Thus, we instead chose to rely on the SNP annotation alone to align strand-ambiguous SNPs to the + strand, with the expectation that this approach would yield fewer strand misalignments compared to invoking the “align_by_maf” flag.

V. Imputation software and computing resources

Imputation analyses were performed using IMPUTE version 2, a freely available software program (see section IX, Web resources). We imputed chromosomes in segments due to (1) IMPUTE2 reports of improved accuracy over short genomic intervals, and (2) our desire to expedite imputation by parallelizing jobs over a multi-core compute cluster. Segments were defined in an iterative process, following a series of recommendations set forth by IMPUTE2 authors. We first created 5 MB segments over the length of each chromosome from the first to last position appearing in the reference panel (i.e. starting at the first imputation target rather position=1). Secondly, segments either overlapping the centromere or at the terminal ends of chromosomes were then merged into the segment immediately upstream. We then checked each segment for the presence of type 0 SNPs, as it is not logical to impute over an interval with no imputation target SNPs. These checks led to additional merging of centromere-adjacent segments on chromosomes 1, 3, 9, 16, and X. Ultimately we divided 23 chromosomes into 552 total segments, ranging from 6 segments on chromosomes 21 to 47 segments on chromosome 2. (Note that while IMPUTE2 provides recommendations for the segmentation method, it is up to the user to implement these criteria and actually define the segments.)

Lastly, we assessed our segmentation scheme in light of the recommendation from IMPUTE2 authors that each segment contain at least some observed GWAS (i.e. type 2) SNPs. Using Illumina HumanOmni2.5-4v1 array SNPs, we calculated an average density of 4,415 GWAS SNPs per segment (range 4-11,610; interquartile range 3,652-4,993). We took this as evidence that GWAS SNPs would be adequately represented in our proposed segments.

By default, IMPUTE2 flanks imputation segments with a 250 kb buffer, where type 2 SNPs are used to estimate haplotypes structure but ultimately discarded from the imputation output. We chose to double the buffer size to 500 kb, which is closer to the 1 MB buffer size the CC has previously used with BEAGLE imputation software. An example of the command line syntax used to run IMPUTE2 on the first 5 MB segment of chromosome 22 is shown below. Note the inclusion of the “-os 0 2” option, which specifies that only SNPs of types 0 and 2 should be written to imputation output files (i.e. removes type 3 “study only” SNPs from output).

```
impute2 -use_prephased_g -m genetic_map_chr22_combined_b37.txt \  
-h ALL_1000G_phaselintegrated_v3_chr22_impute.hap.gz \  
-l ALL_1000G_phaselintegrated_v3_chr22_impute.legend.gz \  
-int 16000001 2.1e+07 -buffer 500 -allow_large_regions \  
-known_haps_g HRS_chr22.haps.gz \  
-filt_rules_l ma.cnt.gte4.allpanels<1 sv.indel>0 \  
-o HRS_chr22.set1.gprobs -os 0 2 \  
-i HRS_chr22.set1.metrics -verbose
```

Imputation jobs were run in parallel on a compute cluster consisting of eight compute nodes, each containing two Intel Xeon E5645 Six-Core processors (12 MB cache), 96 GB of memory, and 1.5 TB of local storage. Due to the input of pre-phased haplotypes, each ~5 MB segment was

imputed in under ~6 hours. We temporarily re-configured each 12-core node to accept only 8 jobs at a time, after several nodes were sent into a suspended alarm state when fully loaded with 12 IMPUTE2 jobs at once. Presumably this computational bottleneck was due to the large HRS sample size, as we have not had to modify our compute cluster configuration for previous IMPUTE2 projects involving smaller datasets.

VI. Imputation output

Imputation output files are divided by chromosome, where “23” denotes chromosome X. All study participants are subject to the same data use limitations (i.e. non-profit research use only), thus alleviating the need to further divide the output by consent level

For more information on the file formats described below, see Web Resources: “IMPUTE2 file format descriptions.”

a. Phased output

Results from the SHAPEIT “pre-phasing” step are posted as gzip compressed “.haps” and “.sample” files, both in IMPUTE2 input format. The SHAPEIT phasing type (trio, duo, or unrelated) is available in Supplementary Files accompanying this report. Regardless of the user’s desire for phased input haplotypes, the “.sample” files will likely be necessary for any downstream analyses, as sample identifiers are not included in the imputation output. The order of samples in the “.sample” files is the order of individuals in the imputation output files described below.

b. Genotype probabilities

Imputation results are posted in chromosome-specific genotype probabilities files (“gprobs”). Our first step in creating these files from the raw IMPUTE2 output was to zero out any imputed genotypes in regions affected by gross chromosomal anomalies (see section 7 of the genotype QC report for details on anomaly detection). A sample’s genotypes were zeroed out across the entire length of any imputation segment overlapping with or containing a gross chromosomal anomaly. Included in the supplementary files section of this report are (1) the chromosome and base pair coordinates of each imputation segment and (2) a list of all anomalous subject-segment combinations, where imputed genotypes were set to missing (i.e. 0.33 0.33 0.33, or equal probabilities across the three genotype classes). After imputation segments were processed for anomalies, they were combined into per-chromosome .gprobs file, via the Unix ‘cat’ command.

The first five columns in these output files correspond to SNP ID, rs ID, map position, and the two SNP alleles, where the first allele shown is designated “allele A” and the second is designated “allele B.” Each subsequent set of three columns corresponds to the genotype probabilities of the three genotype classes (AA, AB, and BB) for a single individual. These genotype files contain two SNP types as defined in the IMPUTE2 algorithm: type 0

(imputation target) and type 2 (imputation basis). The SNP type for each line of the genotype probabilities files can be determined using the accompanying metrics files. Note there are no sample identifiers in the probabilities files, necessitating the use of auxiliary files to align imputed probabilities with sample information (see VI-a, above).

c. Quality metrics

Each genotype probabilities file is accompanied by a SNP annotation and quality metrics file, with each row of a genotype file corresponding to a row in the SNP annotation file. These metrics files were output by IMPUTE2 (the “-i” or “info” file); the only modifications we made were to (1) combine segmented files into one metrics file per chromosome and (2) delete the somewhat redundant “snp_id” field. Columns in these files are defined below, based on IMPUTE2 online documentation (see Web Resources).

- **rs_id:** SNP identifier. For variants in dbSNP, the reference SNP (rs) number. Otherwise, the naming convention “chr#-position” is used. Note that where a single position is identified differently in the study and reference data (possible for type 2 SNPs only), this field reflects the identifier from the study dataset rather than from the reference.
- **position:** Base pair position (GRCh37)
- **exp_freq_a1:** Expected frequency of “allele A” (equivalent to “allele 1”) in the genotype probabilities output file
- **info:** A statistical information metric, which is highly correlated with the squared correlation metrics output by BEAGLE⁷ and MACH¹⁶. (For a more in-depth comparison between these metrics, see the supplementary information in Marchini and Howie, 2010.) Values range from 0 to 1, where 1 means no uncertainty in the imputed genotypes. As noted in the IMPUTE2 online documentation, negative “info” scores can occur when the imputation is very uncertain, and -1 is assigned to the value when it cannot be calculated (i.e. is undefined). Note type 2 SNPs will have “info” values of ~1. For type 0 SNPs, however, the “info” metric is useful for filtering imputed results prior to downstream analyses, as discussed further in section VI-e.
- **certainty:** Average certainty of best-guess genotypes. This metric is also sometimes referred to as the “quality score” (QS) and is calculated as the average of the maximum probability across all samples for a given SNP.
- **type:** Internal type assigned to each SNP where type 0 denotes imputed SNPs (in 1000 Genomes but not study data) and type 2 denotes imputation basis SNPs (observed in the study data and used to impute type 0). Note type 3 SNPs have been excluded with the IMPUTE2 option “-os 0 2.” See Figure 2 for a schematic of these SNP types.

Note: the following fields are defined only at type 2 SNPs, which are involved in leave-one-out masking experiments (see section VI-d).

- **concord_type0**: Concordance between observed and most likely imputed genotype
- **r2_type0**: Squared correlation between observed and imputed allelic dosage
- **info_type0**: “Info” quality metric for a type 2 SNP treated as type 0 (i.e. when it was masked)

Figure 3 includes distributions of the “info” and “certainty” metrics for all imputed SNPs (panels A and B, respectively). In Figure 3C, average “info” scores are plotted in SNPs grouped by imputed MAF (bin sizes of 0.1), demonstrating the relationship between MAF and imputation quality. While average “info” scores at SNPs with MAF < 0.10 fall below 0.9, the remaining SNPs (those with MAF > 0.10) have average “info” scores > 0.9. We also plotted these metrics by chromosome, to assess quality in the slightly more complicated X chromosome imputation. As seen in Figure 4, the X chromosome does not appear to be an outlier, indicating that imputation quality at X chromosome SNPs is comparable to autosomal SNPs.

Downstream analyses of imputed results should take into account the uncertainty of imputed genotypes; however, there is no strong consensus on the best way to do this¹⁴. The CC recommends a SNP level filter, in which only SNPs with a quality metric (IMPUTE2 “info” or BEAGLE allelic r^2 , e.g.) above a certain cutoff value are taken forward into downstream analyses. For example, there is precedent for including only SNPs with a quality metric of ≥ 0.3 ¹⁴. Other threshold values > 0.3 are also reasonable based on the user's desired balance between stringency and inclusivity. In this imputation, choosing a threshold of > 0.3 would retain 97% of all imputed SNPs for downstream analyses, while more stringent thresholds of 0.5 and 0.8 would retain 92% and 75% of imputed SNPs, respectively. For a more detailed discussion of how to interpret and apply imputation quality metrics, see Marchini and Howie (2010, including supplementary information).

Another filtering approach is at the level of imputed genotypes. There is precedence for only analyzing genotypes imputed at a probability ≥ 0.9 and zeroing out all remaining genotypes¹⁷. However, genotype-level filtering does not make use of the full information at a given marker and therefore may be less desirable than the SNP level filters described above.

d. Masked SNP analysis

A common way to assess imputation quality, beyond the theoretical calculations of accuracy discussed above, is to intentionally “mask” a subset of the SNPs genotyped in the study sample (i.e. remove from the imputation basis), impute the masked SNPs as if they were unobserved, and then compare these imputed results to the observed genotypes. The comparison can be made to either (1) the most likely imputed genotype, yielding a somewhat coarse concordance measure and/or (2) the estimated allelic dosage, yielding a more granular correlation measure.

Consider imputed results represented as the probability of the AA, AB, and BB genotype. For the i^{th} sample and the j^{th} SNP, the expected A allelic dosage is $E(d_{ij}) = 2 * P(\text{AA}) + 1 * P(\text{AB}) + 0 * P(\text{BB})$. The squared correlation between the expected allelic dosage $E(d_{ij})$ and the observed allelic dosage $O(d_{ij})$ over individuals can be calculated at each masked SNP, assuming the observed genotype is the true genotype. This correlation metric is an empirical version of the imputation r^2 metrics of MACH and BEAGLE, which are highly correlated with the IMPUTE “info” score.

This type of masked SNP analysis is integrated into every IMPUTE2 imputation run: each study SNP (type 2) is removed from imputation in a leave-one-out fashion, imputed (treated as type 0); and then compared to the imputation input. In the metrics files output by IMPUTE2, each type 2 SNP includes results from the masked SNP test, including concordance and correlation between imputed and observed results, as well as the “info” metric from treating the SNP as type 0. Below we assess the quality metrics of all SNPs masked in this imputation, a total of 2,065,320 masked SNPs.

Figure 5 summarizes the concordance and correlation metrics, with masked SNPs binned according to MAF in the observed study genotypes (0.01 intervals). The first panel (A) shows the number of SNPs per MAF bin and, on the secondary y-axis, the fraction of SNPs in the bin with “info_type0” ≥ 0.8 . In panels B and C, each data point indicates the average value of all SNPs in that MAF bin for the metric indicated on the y-axis. The black data series include all masked SNPs while the gray data series excludes SNPs with “info_type0” < 0.8 . The metric shown in panel (B) is the correlation between masked and imputed allelic dosages; the metric in panel (C) is the concordance: the fraction of identical genotypes between the most likely imputed and observed.

Several salient points emerge from these graphs. Firstly, there is a decline in empirical dosage r^2 for low-frequency variants ($\text{MAF} < 0.05$). As MAF increases, however, average correlation values level off to > 0.9 . Secondly, the differences between unfiltered (black points) and filtered (gray points) data series demonstrate the utility of filtering by the “info” quality metric, which is available for all imputed SNPs. This filtering improves the quality metrics profile for masked SNPs across the entire range of MAF bins. Thirdly, Figure 5C illustrates how overall concordance is heavily influenced by MAF, as for SNPs with $\text{MAF} < 5\%$ simply assigning imputed genotypes to the major homozygous state would yield $> 90\%$ concordance¹⁹. Thus, there is a bias of high concordance values at low MAF SNPs, where major homozygotes are likely to be imputed “correctly” just by chance. To alleviate this bias, in Table 3 we report average concordance and correlation values in two groups of masked SNPs: $\text{MAF} < 0.1$ and $\text{MAF} \geq 0.1$.

Users should note the following aspects of this and other masked SNP tests. While converting imputed probabilities to most likely genotypes is not recommended for association testing, it provides an easily interpretable quality metric for masked SNP tests. Furthermore, concordance can also be reported by averaging over all masked genotypes, rather than by calculating a concordance rate at each masked SNP and then taking the average of those per-SNP values as we have done here. The former way of calculating this metric often leads to higher mean concordance, especially when imputed genotypes are filtered on maximum probability.

Lastly, when discussing imputation quality there can be several different meanings of “efficiency.” In Figure 5, the second column of graphs illustrates one definition: the fraction of imputed SNPs passing a given quality filter (“info” ≥ 0.8 , e.g.). This metric is quite high in most MAF bins > 0.1 . An alternate meaning of imputation “efficiency” is the fraction of samples imputed above a given maximum probability threshold (probability ≥ 0.9 , e.g.), calculated at each SNP. This metric is relevant if one were filtering imputed data at the genotype level rather than on a per SNP level, as it equates to the fraction of samples whose data will be used at each SNP. However, given that genotype-level filtering is not recommended, here we do not include the per-SNP efficiency metric described above. Users can easily produce this metric by taking the imputed genotype data files; converting into most likely genotypes, using a probability threshold; and then calculating the percent missingness at each SNP.

e. Downstream analysis

Many references are available for users desiring further information on imputation methods, including recommendations and caveats for downstream analyses^{1,2,11,14,19}. Programs for performing association analyses with imputed genotype probabilities include PLINK (with the `--dosage` option: <http://pngu.mgh.harvard.edu/~purcell/plink/dosage.shtml>), MACH2qtl/dat¹⁶, SNPTEST²⁰, ProbABEL²¹, BIMBAM²², SNPStat²³, and the R package snpMatrix²⁴. For a comparison of methods to account for genotype uncertainty in imputed data, see Zheng et al²⁵. IMPUTE is part of a suite of GWAS software that is useful in post-imputation data filtering and formatting tasks (see Web Resources, “Genome-wide Association Study Software”). For example, QCTOOL may be used to filter imputed data by the IMPUTE2 “info” score as recommended in section VI-c.

VII. Summary

We have performed genotype imputation in the Health Retirement Study, using a worldwide 1000 Genomes Project reference panel and IMPUTE2 software. The imputed genotypes and accompanying marker annotation and quality metrics files are available through the authorized access portion of the dbGaP posting.

These imputation analyses were performed and documented by Sarah Nelson, under the leadership of Cathy Laurie and Bruce Weir, within the Genetics Coordinating Center at the University of Washington (UW) in Seattle, WA. Additional guidance was provided by Brian Browning (Division of Medical Genetics, Department of Medicine, UW), Sharon Browning (Department of Biostatistics, UW), and Bryan Howie (Department of Human Genetics, University of Chicago). Guidance on pre-phasing and a pre-release version of SHAPEIT2 were provided by Olivier Delaneau and Jonathan Marchini (Department of Statistics, University of Oxford). Questions on SHAPEIT2 may be directed towards the authors (olivier.delaneau@gmail.com, marchini@stats.ox.ac.uk).

VIII. References

1. Browning, S. Missing data imputation and haplotype phase inference for genome-wide association studies. *Hum Genet* **124**, 439-50 (2008).
2. Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. *Annu Rev Genomics Hum Genet* **10**, 387-406 (2009).
3. Howie, B., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet* **5**, e1000529 (2009).
4. Laurie, C.C. et al. Quality control and quality assurance in genotypic data for genome-wide association studies. *Genet Epidemiol* **34**, 591-602 (2010).
5. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559-75 (2007).
6. Delaneau, O., Marchini, J. & Zagury, J.F. A linear complexity phasing method for thousands of genomes. *Nat Methods* **9**, 179-81 (2011).
7. Browning, B. & Browning, S. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. *Am J Hum Genet* **84**, 210-23 (2009).
8. B. Howie, J.M., and M. Stephens. Genotype Imputation with Thousands of Genomes. *G3: Genes, Genomics, Genetics* **1**, 457-470 (2011).
9. Frazer, K. et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851-61 (2007).
10. Altshuler, D. et al. Integrating common and rare genetic variation in diverse human populations. *Nature* **467**, 52-8 (2010).
11. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. *Nat Rev Genet* **11**, 499-511 (2010).
12. Durbin, R.M. et al. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061-73 (2010).
13. Jostins, L., Morley, K.I. & Barrett, J.C. Imputation of low-frequency variants using the HapMap3 benefits from large, diverse reference sets. *Eur J Hum Genet* **19**, 662-6 (2011).
14. de Bakker, P. et al. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. *Hum Mol Genet* **17**, R122-8 (2008).
15. Nelson, S.C., Laurie, C.C., Doheny, K.F. & Mirel, D.B. Is 'forward' the same as 'plus'?...and other adventures in SNP allele nomenclature. *Trends in Genetics* **28**, 361-363 (2012).
16. Li, Y., Willer, C.J., Ding, J., Scheet, P. & Abecasis, G.R. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol* **34**, 816-34 (2010).
17. Nothnagel, M., Ellinghaus, D., Schreiber, S., Krawczak, M. & Franke, A. A comprehensive evaluation of SNP genotype imputation. *Hum Genet* **125**, 163-71 (2009).
18. Lin, P. et al. A new statistic to evaluate imputation reliability. *PLoS One* **5**, e9697 (2010).
19. Guan, Y. & Stephens, M. Practical issues in imputation-based association mapping. *PLoS Genet* **4**, e1000279 (2008).
20. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet* **39**, 906-13 (2007).
21. Aulchenko, Y.S., Struchalin, M.V. & van Duijn, C.M. ProbABEL package for genome-wide association analysis of imputed data. *BMC Bioinformatics* **11**, 134 (2010).
22. Servin, B. & Stephens, M. Imputation-based analysis of association studies: candidate regions and quantitative traits. *PLoS Genet* **3**, e114 (2007).
23. Hu, Y.J., Lin, D.Y. & Zeng, D. A general framework for studying genetic effects and gene-environment interactions with missing data. *Biostatistics* **11**, 583-98 (2010).

24. Clayton, D. & Leung, H.T. An R package for analysis of whole-genome association studies. *Hum Hered* **64**, 45-51 (2007).
25. Zheng, J., Li, Y., Abecasis, G.R. & Scheet, P. A comparison of approaches to account for uncertainty in analysis of imputed genotypes. *Genet Epidemiol* **35**, 102-10 (2011).

IX. Web resources: data and software

The 1000 Genomes Project. "About the 1000 Genomes Project." Retrieved from <http://www.1000genomes.org/about> on March 7, 2011.

The 1000 Genomes Project. IMPUTE2 Haplotypes. Retrieved from http://mathgen.stats.ox.ac.uk/impute/data_download_1000G_phase1_integrated.html on April 19, 2012.

The 1000 Genomes Project. Phase1 integrated release version3 [released April 2012]. Available from <ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/>

Browning B (c2007-2010) BEAGLE Utilities [software]. Available from http://faculty.washington.edu/browning/beagle_utilities/utilities.html

Delaneau O (Version v v1.532, c2011) SHAPEIT: Segmented HAPlotype Estimation and Imputation Tool [software]. Available from <http://www.shapeit.fr/>.

Genome-wide Association Study Software Suite : CHIAMO, GTOOL, IMPUTE, SNPTEST, HAPGEN, GENECLUSTER, BIA, HAPQUEST (c2007). Available from <http://www.stats.ox.ac.uk/~marchini/software/gwas/gwas.html>.

Howie B and Marchini J (c2007-2011) IMPUTE version 2.2.2 [software]. Available from https://mathgen.stats.ox.ac.uk/impute/impute_v2.html.

Howie B and Marchini J (September 23, 2010). "Using IMPUTE2 for phasing of GWAS and subsequent imputation," a document distributed with IMPUTE2 example code. Available at http://mathgen.stats.ox.ac.uk/impute/prephasing_and_imputation_with_impute2.tgz.

Illumina, Inc. (2006). "TOP/BOT" Strand and "A/B" Allele [Technical Note]. Available from http://www.illumina.com/documents/products/technotes/technote_topbot.pdf

IMPUTE 2 background. Retrieved from https://mathgen.stats.ox.ac.uk/impute/impute_background.html, February 21, 2012.

IMPUTE2 file format descriptions. Retrieved from http://www.stats.ox.ac.uk/~marchini/software/gwas/file_format.html, February 7, 2012.

Freeman C and Marchini J. (c2007-2011) GTOOL Software Package (Version 0.7.5) [software]. Available from <http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html>.

Purcell S. PLINK (Version 1.07, c2009) [software]. Available from <http://pngu.mgh.harvard.edu/purcell/plink/>

X. Tables

Table 1. SNP summary

Chromosome	Study SNPs [†]	Imputation basis ^{††}	Imputation Output
1	171,848	160,997	1,639,361
2	180,770	169,933	1,781,822
3	152,123	142,934	1,501,569
4	141,498	132,660	1,517,997
5	135,565	127,185	1,378,896
6	134,984	126,771	1,348,512
7	119,565	112,601	1,228,557
8	117,334	110,601	1,188,831
9	96,854	91,598	911,106
10	111,258	104,636	1,040,951
11	108,456	101,929	1,038,281
12	104,377	97,955	1,006,836
13	77,080	72,462	756,741
14	71,602	67,478	689,733
15	67,755	63,870	618,025
16	72,862	68,807	664,752
17	62,966	59,186	572,210
18	64,189	60,615	597,557
19	45,210	42,471	469,034
20	53,871	51,104	469,329
21	29,884	28,178	289,475
22	32,062	30,436	284,543
X	43,193	40,913	637,930
Totals	2,195,306	2,065,320	21,632,048

† Study SNPs passing pre-imputation filters (IMPUTE2 SNP types 2 and 3).

†† Study SNPs passing pre-imputation filters and overlapping with the reference panel (type 2).

Imputation output is the sum of imputation basis (type 2) and imputation target (type 0) SNPs. Type 0 SNPs have been restricted to those with at least 4 copies of the minor allele in AFR, AMR, ASN, or EUR reference samples.

Table 2. An overview of the 1,092 samples in the 1000 Genomes Project worldwide reference panel (phase I integrated variant set v3, March 2012), which was used to impute all study participants. Each population was assigned to one of four continental groupings: African (AFR), American (AMR), Asian (ASN), and European (EUR). All haplotypes in the phased reference panel are for unrelated, founder individuals only. This table is based on reference panel data downloaded from IMPUTE2 and the sample summary provided by the Project (see Web resources).

Full Population Name	Abbreviation	Number of Samples
African Ancestry in Southwest US	ASW	61
Luhya in Webuye, Kenya	LWK	97
Yoruba in Ibadan, Nigeria	YRI	88
<i>Total African ancestry</i>		<i>246</i>
Colombian in Medellin, Colombia	CLM	60
Mexican Ancestry in Los Angeles, CA	MXL	66
Puerto Rican in Puerto Rico	PUR	55
<i>Total American ancestry</i>		<i>181</i>
Han Chinese in Beijing, China	CHB	97
Han Chinese South, China	CHS	100
Japanese in Tokyo, Japan	JPT	89
<i>Total Asian ancestry</i>		<i>286</i>
Utah residents (CEPH) with Northern and Western European ancestry	CEU	85
Toscani in Italia	TSI	98
British in England and Scotland	GBR	89
Finnish in Finland	FIN	93
Iberian populations in Spain	IBS	14
<i>Total European ancestry</i>		<i>379</i>

Table 2. Quality metrics for all masked SNPs, dichotomized into groups of MAF < 0.1 vs. MAF ≥ 0.1. The second column shows the number of SNPs in each MAF group. Mean and median values are presented for overall genotype concordance and empirical dosage r² (in IMPUTE2 metrics files, labeled as “concord_type0” and “r2_type0,” respectively). No “info” threshold has been applied here, such that all masked and imputed SNPs in each MAF category are included in these averages.

MAF (in study samples)	Number of SNPs	Mean (Median) Overall Concordance	Mean (Median) empirical dosage r²
< 0.1	1,059,523	0.989 (0.998)	0.834 (0.919)
≥ 0.1	1,005,797	0.973 (0.994)	0.951 (0.994)

XI. Figures

Figure 1. Principal component analysis of 12,507 unique study participants and 1,230 HapMap controls, using a set of 96,134 autosomal SNPs pruned for both long and short range linkage disequilibrium. For study samples, color-coding is according to self-identified race while symbol denotes ethnicity (Hispanic or non-Hispanic). HapMap samples are color coded by membership in 1 of 11 Phase 3 populations: ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Tuscan in Italy; and YRI: Yoruban in Ibadan, Nigeria. The percent variance explained by each of these first two components is noted on the axis labels. (Also Figure 11 from the genotype QC report.)




Figure 2. A schematic of SNP types as defined in the IMPUTE2 imputation algorithm. Each individual is represented by a unique color in the horizontal bar(s), and alternate alleles at each SNP are represented as A and B. Section (A) represents phased reference haplotypes, where two samples (4 phased chromosomes) are shown. Section (B) represents three study samples with SNP genotype calls, as would be observed in GWAS array experiment. Section (C) identifies the SNP type of each position shown. “Type 2” SNPs have data in both the reference and the study samples: positions 1, 4, 6, 8, and 11. “Type 0” SNPs have data in the reference but not in the study samples: positions 3, 5, 9-10, and 12. Thus, data at “type 2” SNPs (imputation basis) are used to impute “type 0” SNPs (imputation target) in the study samples. “Type 3” SNPs are those in study samples but not in the reference; ultimately, these SNPs are extraneous to the imputation, which is why they are shown in white text. This figure is a based off of IMPUTE2 background documentation (see Web Resources).






Figure 3. Summaries of quality metrics at all imputed SNPs. Panel A shows the distribution of the “info” quality metric, with a dashed line indicating a potential 0.3 threshold value. Panel B is the distribution of “certainty,” the average certainty of best-guess genotypes. Panel C summarizes the relationship between the “info” score and MAF. The secondary axis indicates the count of SNPs in each MAF bin (0.01 intervals).

A)



B)



C)





Figure 4. A comparison of imputation quality metrics by chromosome for all imputed SNPs, “info” in panel A and “certainty” in panel B. Outlier values are not displayed in these box plots. On the x-axis, “23” denotes the X chromosome.

A)



B)






Figure 5. Quality metrics for all masked SNPs, grouped into MAF bins at 0.01 intervals. Panel (A) shows the number of SNPs per MAF bin and, on the secondary y-axis, the fraction of SNPs in the bin passing an “info” filter threshold of ≥ 0.8 . Panel (B) plots the average empirical dosage r^2 metric per MAF bin, both before and after filtering on the “info” score (black and gray data series, respectively). Similarly, panel (C) is the concordance between the observed and the most likely imputed genotype at masked SNPs within each MAF bin, with and without the “info” filter.


A)



B)



C)



XII. Supplementary files

- a. **Chromosome anomalies.** Genotypes in imputed segments of the genome harboring a gross chromosomal anomaly have been filtered out of the final genotype probabilities files. The following two supplementary files provide information related to this chromosomal anomaly filtering.
1. The file “imputation_segments.csv” is a list of the chromosome and base pair coordinates of each imputation segment (552 total). These coordinates were supplied to IMPUTE2 with the “-int” flag, to define imputation chunks. The fields in this file are:
 - **chrom:** chromosome
 - **segment:** imputation segment ID
 - **mb.start:** start coordinate, in mega base pairs
 - **mb.end:** end coordinate, in mega base pairs
 2. The file “filtered_map.txt” is a list of subject-segment combinations where imputed genotypes were set to missing (i.e. 0.33 0.33 0.33, or equal probabilities across the three genotype classes). The fields in this file are:
 - **subjectID:** participant level identifier assigned by the CC, used in imputation output
 - **chrom:** chromosome
 - **segment:** imputation segment ID
- b. **SNP selection.** The file “snp.qualfilter.txt” is a list of genotyped SNPs passing CC recommended quality filters from genotype cleaning process and also mapped to build 37. This list may be used to construct a keeplist for use with the PLINK `--extract` flag, to perform the initial sub setting of SNPs from the binary file (see II-c). The SNP dimension in this file corresponds to the “Study SNPs” column of the SNP Summary in Table 1. The columns in these text files are:
- **rs.id:** refSNP identifier in build 37.
 - **chrom:** chromosome number, in build 37 mapping.
- c. **Sample-subject mapping.** The identifier used in the imputation output is the “subjectID.” A mapping of “subjectID” to “scanID,” which corresponds to one genotype scan, is provided in the file “subjectid2scanid.txt.” The columns in this file are:
- **family:** family identifier
 - **local.subjectID:** local (study investigator’s) participant level identifier
 - **subjectID:** participant level identifier assigned by the CC, used in imputation output
 - **scanID:** sample level identifier
 - **sex:** male (M) or female (F)
 - **phasing.type:** Sample type in the SHAPEIT phasing analysis (“type” in SHAPEIT log files). Possible values are: Unr, DuoC, DuoM, DuoF, TrioC, TrioM and TrioF, which stand for unrelated, duo child, duo mother, duo father, trio child, trio mother, and trio father, respectively.